Free Trial
NASDAQ:ZNTL

Zentalis Pharmaceuticals Q2 2025 Earnings Report

Zentalis Pharmaceuticals logo
$1.78 +0.07 (+3.78%)
As of 10:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zentalis Pharmaceuticals EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Zentalis Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zentalis Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zentalis Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Zentalis Pharmaceuticals Earnings Headlines

Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
See More Zentalis Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zentalis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your email.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

View Zentalis Pharmaceuticals Profile

More Earnings Resources from MarketBeat